AURORA CANNABIS CHS CLASS ACTION CERTIFIED Français

TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death.
On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants.
The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website.
The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS.
The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants.
The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims.
.
Sotos Class Actions
55 University Avenue, Suite 600
Toronto, ON M5J 2H7
[email protected]
1-877-294-9747 (toll free)
For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Canada Standard

14 minutes ago

• Canada Standard

Hainan free trade port moves to forefront of China's opening-up drive

HAIKOU, June 21 (Xinhua) -- For Canadian visitor Stephanie Wing See Yau, the therapy experience at a care center in Bo'ao, a coastal city in China's southernmost island province of Hainan, felt more like "a vacation." "This place is top-notch. They cater to so many aspects of wellness, not just physical, but mental too," she told Xinhua during her stay in the Boao Lecheng International Medical Tourism Pilot Zone, which hosts over 30 top-tier domestic and international medical institutions. Thanks to special policy support, the pilot zone has introduced 485 cutting-edge medicines and medical devices that are licensed abroad but not yet available in the domestic market. The policy has benefited more than 130,000 patients, including individuals like Yau. Her four-day experience -- blending advanced health screenings, traditional therapies, tea ceremonies, and cultural immersion -- offers much more than just a chance to relax. It showcases a tangible outcome of a key move in China's opening-up strategy: the transformation of Hainan into a Free Trade Port (FTP). As the Hainan FTP is set to begin independent customs operations by the end of the year, it is poised to become not only a tourist haven but also a pivotal gateway for China's opening-up drive. FRONTIER FOR FREE-FLOWING FACTORS A central component of this transformation is the Lecheng medical tourism pilot zone. A total of 25 medical tourism routes have been rolled out to cater to a wide range of needs, including traditional Chinese medicine, chronic disease care, luxury diagnostics and cosmetic rehab, garnering popularity among visitors from countries such as Indonesia, Russia, Spain, and beyond. In 2024, the medical special zone attracted over 410,000 medical visitors, up 36.76 percent year on year. Lecheng is only one part of Hainan's wider push for opening up. Beyond the medical sector, the province has been fast-tracking foreign access across sectors ranging from finance and education to communication and high-tech industries, as China aims to build an FTP with global top-tier trade standards. Hainan, supported by the country's vast domestic market and its strategic positioning, stands as a vital hub that connects the world's second-largest economy with global markets. The FTP is gearing up to be "a pivotal gateway leading China's new era of opening-up," said Chi Fulin, head of the China Institute for Reform and Development. With independent customs operations imminent, the FTP's policy framework, underpinned by features like zero tariffs, low tax rates, simplified tax systems and facilitated factor flows, has taken shape. For firms in Lecheng, a zero-tariff policy on medical imports has saved nearly 8.2 million yuan (about 1.14 million U.S. dollars) in duties since December 2024. The start of independent customs operations will represent a concrete step toward building a major gateway for China's high-level opening-up, Chi said. INSTITUTIONAL OPENING-UP LURING FOREIGN CAPITAL As Hainan FTP has prioritized institutional integration and coordination across trade, finance and regulatory systems, experts believe this will create a powerful driving force for the development of the FTP and contribute to China's high-standard opening up strategy. Official data showed that so far, the province has rolled out a total of 158 institutional innovation cases. These reform measures include technology-empowered public tendering, one-stop business licensing, and a specialized IP zone to support the seed industry. Hainan FTP serves not only as a testing ground for free-flowing goods, services and data, but as a frontier for the innovation of regulations and mechanisms, said Zhou Xiaochuan, vice chairman of the Boao Forum for Asia (BFA). With its optimized business environment, Hainan has emerged as a premier foreign investment destination, ranking among China's top performers. In 2024, the number of foreign-invested enterprises in Hainan rose 19.2 percent year on year, while its foreign direct investment volume climbed to the tenth spot nationally. To date, Hainan has attracted investment from 158 countries and regions, while its economic openness ratio -- the ratio of total trade to GDP -- more than doubled from 17.3 percent in 2018 to 35 percent in 2024. High-profile events held in the province like the BFA, a premier platform advocating openness and multilateral cooperation, and the China International Consumer Products Expo, the largest consumer expo in the Asia-Pacific region, offer global investors dynamic gateways to observe the country's evolving openness agenda. DFS, the travel retail company of the luxury goods conglomerate LVMH, in 2024 sealed its largest single investment in 60 years to launch a landmark complex in Yalong Bay of Sanya, the well-known tropical resort city in Hainan. The project will merge luxury retail, hotels and entertainment, with the goal of building a top destination for luxury shopping and tourism. "Hainan FTP embodies China's commitment to high-standard openness," said Nancy Liu, president of DFS China. China's special economic zones, like Hainan FTP and the 21 pilot free trade zones, serve as pivotal engines for industrial transformation and opening up, Chi noted, highlighting their role as "growth accelerators for both regional and global economies." When the independent customs operations begin, Hainan FTP will create key opportunities for international enterprises to access China's domestic market more efficiently, and play a greater role in enhancing market connectivity with global markets through service trade-focused regulatory alignment, he added.

Cision Canada

8 hours ago

• Cision Canada

STATEMENT - CMA reflects on National Indigenous Peoples Day Français

OTTAWA, ON, June 21, 2025 /CNW/ - On this National Indigenous Peoples Day, the Canadian Medical Association (CMA) reflects on the rich history, strength and resilience of First Nations, Inuit and Métis Peoples. This year marks the 10 th anniversary of the Truth and Reconciliation Commission of Canada's report, which exposed the devastating legacy of Canada's residential schools, and the sixth anniversary of the report from the National Inquiry into Missing and Murdered Indigenous Women and Girls. We acknowledge and honour the stories that survivors have shared to help guide us toward a better future. With great humility, we continue our own reconciliation journey led by an Indigenous Guiding Circle composed of health leaders, Elders and Knowledge Keepers. This journey includes working in partnership to combat anti-Indigenous racism in health care and to support the medical profession in making the system safer for First Nations, Inuit and Métis patients and providers. In updating our Code of Ethics and Professionalism, our goal is to better reflect physicians' shared values in supporting patients and providers from Indigenous communities. Alongside Indigenous partners, we're leveraging our voice to also call on the federal government to reintroduce important First Nations clean water legislation and support First Nations, Inuit and Métis-led health care. Our commitment extends to amplifying Indigenous voices and highlighting critical issues through the Indigenous Health Journalism Fellowship. On National Indigenous Peoples Day, we recognize the importance of acknowledging the truth, rebuilding trust and taking the steps necessary to fulfill our promise of transforming the health system to provide culturally safe, trauma-informed care for Indigenous Peoples. Dr. Margot Burnell President, CMA SOURCE Canadian Medical Association

Cision Canada

10 hours ago

• Cision Canada

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions alongside comprehensive benefits for body weight, blood pressure and blood lipid profiles. In a Phase 2b clinical trial, the bofanglutide injection showed superior HbA1c and body weight reduction than semaglutide (Ozempic ®) after 24 weeks of bi-weekly treatment in patients with T2DM, along with an acceptable safety and tolerability profile. In a Phase 2 clinical trial, the once-weekly insulin GZR4 injection demonstrated comparable efficacy and safety profiles in patients with T2DM after 16 weeks of treatment. Notably, GZR4 injection achieved superior HbA1c reduction in patients with inadequate glycemic control on prior basal insulin therapy compared to once-daily insulin degludec (Tresiba ®). BEIJING and BRIDGEWATER, N.J., June 21, 2025 /CNW/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: announced that the company presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection and once-weekly basal insulin analog GZR4 injection during a poster presentation at the American Diabetes Association (ADA)'s 85th Scientific Sessions. Bofanglutide injection and GZR4 injection are investigational drugs that have not yet been launched in any country. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications. Bofanglutide injection: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bofanglutide (GZR18) Injection in Chinese Patients with Type 2 Diabetes Mellitus (T2DM) In this Phase 2a clinical trial (NCT06256523), 36 adults with T2DM who had inadequate glycemic control through diet and exercise and/or irregular use of antidiabetic medications, were randomized to receive either bofanglutide injection (N=27) or placebo (N=9) once weekly (QW) for 23 weeks, with a dose escalating from 1.5 mg to 13 mg. The key efficacy endpoint was HbA1c change from baseline to week 23. After 23 weeks of treatment, the mean HbA1c change from baseline in the bofanglutide groups was -1.81% compared to 0.12% in the placebo group, with an estimated treatment difference of -1.93% points *. The proportion of participants achieving an HbA1c target of <7.0% and ≤6.5% was 57.7% and 46.2%, respectively, compared to zero in the placebo group. In terms of weight management, participants treated with bofanglutide experienced a mean reduction in body weight of 6.92 kg from baseline, corresponding to a 9.3% decrease, compared to a minimal reduction of 1.2% in the placebo group. Furthermore, bofanglutide showed comprehensive improvements over placebo in multiple metabolic parameters, including fasting plasma glucose (FPG), glycated albumin (GA), waist circumference (WC), blood pressure, and lipid profiles. In terms of safety, bofanglutide was well tolerated in patients with T2DM. Consistent with known GLP-1 RAs, the most common adverse events were gastrointestinal-related, primarily observed during the early dose-escalation period with mostly mild to moderate in severity. No hypoglycemic events or investigational product-related serious adverse events were reported during the study. Bofanglutide injection: A Multicenter, Randomized, Open-label, Active comparator-controlled Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of bofanglutide Injection versus Semaglutide (Ozempic ®) in Chinese Patients with T2DM In this Phase 2b clinical trial (NCT06256549), a total of 272 eligible Chinese patients with T2DM, who had inadequate glycemic control either after lifestyle intervention or despite stable use of oral antidiabetic drugs (OADs) for at least 3 months, were randomized to receive bi-weekly (Q2W) 12 mg (N=55), 18 mg (N=54), 24 mg (N=55) bofanglutide injections, or once-weekly (QW) 24 mg (N=54) bofanglutide injections, or 1 mg semaglutide (Ozempic ®, N=54) for 24 weeks of treatment, including the dose-escalation period. The primary endpoint was HbA1c change from baseline to week 24. After 24 weeks of treatment, the mean reductions in HbA1c from baseline were 1.87%, 2.28%, and 1.94% in the bofanglutide groups at 12 mg, 18 mg, and 24 mg Q2W, respectively, and -2.32% in the 24 mg QW group. All these treatment regimens showed greater HbA1c reductions compared to the semaglutide group (-1.60%), with the 18 mg Q2W and 24 mg QW bofanglutide groups demonstrating statistically significant superiority (p<0.001) *. Among drug-naïve patients with inadequate glycemic control despite lifestyle interventions, the 18 mg Q2W bofanglutide group achieved a mean HbA1c reduction of 2.98%, which was significantly greater than that observed with semaglutide (-2.04%; p<0.001)*. The proportions of patients achieving HbA1c target of <7.0% were 63.0% to 73.6% in the Q2W bofanglutide group, 75.0% in the QW bofanglutide group, and 70.0% in the semaglutide group. For the HbA1c ≤6.5% target, the corresponding proportions were 58.2% to 67.9%, 69.2%, and 62.0%, respectively. Furthermore, the mean change in body weight for all bofanglutide groups from baseline to week 24 ranged from -4.26 to -6.54 kg, compared to -3.25 kg in the semaglutide group *. Bofanglutide also greatly improved FPG, blood pressure, lipid profiles, and other metabolic parameters. In this study, bofanglutide was g enerally well tolerated, with safety and tolerability consistent with other known GLP-1 RAs. The most common adverse events were gastrointestinal-related, mostly mild to moderate in severity, and no sever e hypoglycemic events were observed. GZR4 injection: A Multicenter, Randomized, Open-label, Active-controlled, Treat-to-target Phase 2 Clinical Study Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin degludec (IDeg, Tresiba ®) in Chinese patients with T2DM This Phase 2 clinical study (NCT06202079) enrolled a total of 83 Chinese patients with T2DM who had inadequate glycemic control on OADs (Part A), and 96 patients with inadequate control on OADs combined with basal insulin therapy (Part B). Participants were randomized to receive QW GZR4 injection (Part A: N=42; Part B: N=41) or once-daily IDeg (Tresiba ®) injection (Part A: N=48; Part B: N=48) for 16 weeks of treatment. The primary efficacy endpoint was the change in HbA1c from baseline to week 16. After 16 weeks of treatment, in patients from Part A, the mean change in HbA1c was comparable between GZR4 groups and IDeg groups (−1.50% versus -1.48%, p = 0.90). The proportion of participants achieving HbA1c target of <7.0% was 59.5% in the GZR4 group and 70.7% in the IDeg group, while the proportion achieving HbA1c target of ≤6.5% was 38.1% and 29.3%, respectively. In patients from Part B, GZR4 demonstrated significantly greater HbA1c reduction compared to IDeg (-1.26% vs -0.87%; p<0.01), with a higher proportion of patients achieving HbA1c targets of <7.0% and ≤6.5% (52.1% vs 29.2%; 25.0% vs 10.4%). In addition, improvements from baseline in FPG and time in range (TIR) were comparable between the GZR4 group and IDeg group. GZR4 achieved effective glycemic control without the need for a loading dose at the first administration, while the total weekly insulin dosage (mole) for GZR4 was approximately 40–50% of that for IDeg (p<0.001). In terms of safety, the incidence of adverse events was similar between the two groups. No severe hypoglycemic events or investigational product-related serious adverse events were reported during the study. * The clinical data were presented as mean (SE) value. The detailed results of the above Phase 2 clinical study will be published in a peer-reviewed journal. Conclusion and Future Direction The latest clinical results presented at this year's ADA conference highlight Gan & Lee Pharmaceuticals' leading position in the development of long-acting antidiabetic therapies. Building on these positive outcomes, the company will continue to advance the research and development of innovative treatments for diabetes. Currently, Gan & Lee has initiated and is accelerating large-scale Phase 3 clinical programs in China for bofanglutide injection and GZR4 injections for the treatment of type 2 diabetes, aiming to provide more effective treatment options for patients with diabetes. Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin ®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin ®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin ® 30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin ® 30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine ®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine ®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.